Article abstract-Recent evidence suggests that the vasopressin analogue desglycinamide-arginines-vasopressin (DGAVP) might specifically benefit mild brain trauma patients. We investigated the effect of intranasal DGAVP treatment in 32 patients who had sustained a mild head injury for 3 months in a double-blind, placebo-controlled, matchedpairs study. DGAVP did not have a positive effect on cognitive recovery in this group of mildly affected patients.
NEUROLOGY 1993;43:103-106 Peptides related to the pituitary hormone vasopressin (VP) influence aspects of memory processes and learning in laboratory animals. 1, 2 There have been several clinical studies with vasopressin and related peptides, but the studies differ with respect to the nature of the patients included, methodologic characteristics, pharmacokinetic aspects (dose and route of administration), and the type of VP analogue used.3 Some studies reported beneficial effects of peptide administration, whereas others were n e g a t i~e .~
The majority of positive findings were obtained either in an open, uncontrolled clinical trial with patients4 or in placebo-controlled studies with volu n t e e r~.~~~ A possible explanation for the discrepant findings is that the peptide might have a specific action on particular cognitive processes and not on others. Most studies where the peptide was ineffective involved patients with a complex pattern of neuropsychologic deficits or other symptoms suggestive of profound brain damage. The lack of effect in patients with structural brain damage is not sur-prising because lesions of the relevant brain structures may have destroyed the sites of action of the peptide.
There have been positive effects in mild,4z7 as opposed to severe, brain t r a~r n a .~,~ The efficacy may depend on the extent of structural lesions. Timsit-Berthier et a17 suggested that the peptide effects developed with time, which may indicate that the treatment period should be longer than a few weeks. We therefore hypothesized that the subjects of choice for VP treatment would be those with early and mild cognitive dysfunction, and the duration of the medication should be sufficiently long.3 This is supported by investigations using desglycinamide-arginines-vasopressin (DGAVP) in memory-disturbed patients,1° where peptide effects occurred in mild brain trauma but not in patients with a severe trauma.
Mild head injury (MHI) can cause cognitive dysfunction11-13 which is maximal in the first weeks after injury and gradually tends to res01ve.l~ We studied whether an earlier instituted and longer treatment with intranasal VP has an effect on cognitive and subjective recovery in a selected population of patients who had sustained an MHI.
Methods. Subjects. Consecutively hospitalized patients
who had sustained an MHI were asked to participate in the study on the basis of informed consent. The criteria for inclusion in the study were a post-traumatic amnesia not exceeding 60 minutes, a period of unconsciousness of less than 15 minutes, a Glasgow Coma Score of 13 to 15 on admission, age between 15 and 70 years, and no serious traumatic physical complication. Patients who had drunk alcohol a t the time of the trauma or who had a skull fracture or nose trauma were also excluded. None of the patients had a history of neuropsychiatric disorder.
Patients were assigned pairwise to a treatment regimen with either DGAVP or a placebo (carrier). Both patients a n d staff were blinded to t h e medication. Patients were matched in pairs for age ( f 6 years), sex, and education (+1 level15). The study was approved by the medical ethical council of the hospital. Fourteen eligible patients did not want to participate, and seven patients were excluded because of noncompliance. Thirty-two patients completed the study. Each group consisted of 16 subjects (nine males and seven females). The mean age i n the DGAVP group was 26.1 years (f14.7) and educational level was 5.1 on a 7-point scale (kl.0). The corresponding means for the placebo group were 27.8 years (k12.4) and 4.5 (kO.9).
Postconcussive symptoms. A checklist of postconcussive symptoms was completed, which included headache, nausea, dizziness, difficulties with concentration and memory, fatigue, and sleep disturbances. As these symptoms also occur in healthy individuals,16 the symptoms were scored for the absolute or increased appearance after the injury in comparison with the pretraumatic condition. Patients were considered asymptomatic if they did not complain of any postconcussive symptoms.
Psychometric tests. The following tests were used: (1) Memory task. A visual, computer-assisted version of the Auditory Verbal Learning T e d 7 (AVLT) was presented on a portable microcomputer. 18 The AVLT was adapted for the Dutch language.18J9 The test consists of a list of 15 monosyllabic meaningful words, which are presented for 1 second at 1-second intervals. At the end of the trial the subjects recall the words. Five trials were carried out. The variable used in this study was the total number of correct words over all trials. Different parallel versions of the AVLT were used in each session.
(2) The Concept Shifting Test20 (CST) is a test of visual scanning and conceptual tracking, much like the Trail Making Test. 17 The CST consists of three subtasks. In each subtask the subject has to cross out small circles containing digits or letters in the correct order. The small circles are arranged in a larger circle on a sheet of paper. The subject was requested to perform the task as quickly as possible. In the first subtask (A) the subject has to cross out consecutively numbered (1 to 16) circles, in the second subtask (B) 16 lettered circles (A to P). In subtask C, the subject is presented with 16 circles containing eight digits and eight letters (A to H) and is asked to alternate between the two sequences (l-A-Z-B, etc.). The amount of extra time needed for subtask C represents the concept-shifting score [tC -0.5 (tA + tB); t = time in seconds].
(3) The Stroop Color Word Interference T e d 7 consists of three subtasks. The test examines the speed at which 100 color names (yellow, green, red, and blue) are read (subtask I) and the speed at which 100 colored spots are named (subtask 11). Subtask I11 again involves 100 color names, but the printing ink is different from the color name; the speed a t which the color of the printing ink of the words is named is taken as the test variable. The color word interference score was obtained by subtracting the time needed for subtask I1 from that of subtask I11 (111 -II), and was used as the cognitive parameter.
Design and procedure. Treatments were administered by intranasal spray, each single dose (two puffs) containing either 1 mg DGAVP or placebo (kindly donated by Organon B.V., Oss, The Netherlands). The subjects were instructed to administer themselves four puffs per day (two puffs at breakfast time and two puffs at lunch time); the daily dose was 2 mg DGAVP. The duration of the treatment was 3 months.
Evaluation of the cognitive performance was done by a neuropsychologic assessment a t six time points within the 3-month period. As cognitive recovery after MHI is maximal in the first weeks,14 the interval between test sessions was shortest immediately after the trauma. This interval increased in the later phases after the trauma, since we expected to find the greatest changes in performance a t the beginning of the recovery process. There was one pretreatment assessment at day -1. Treatment started 2 days after MHI (day 0). Six post-treatment assessments were at days 3, 7, 14, 28, 56, and 84.
Drug safety procedure. Liver and renal functions, electrolytes, and total blood count were monitored before entry into the study and at 3 days, 2 weeks, and 8 weeks after the start of treatment.
Statistical analysis. Test scores were analyzed with repeated-measures analysis of variance. 21 The only grouping factor was the treatment variable (DGAVP versus placebo). As recovery after MHI is maximal in the first weeks after the injury, tests were performed at 1 and 3 months after the trauma. Because of the risk of increasing the statistical error due to performing multiple F tests, the Bonferroni correction22 was applied to adjust the significance levels. Therefore, a probability level of less than 0.005 was considered significant.
Results.
The results of the cognitive tasks are pre- (table) . With respect to the DGAVP treatment, there was no significant time X DGAVP interaction for any of the cognitive parameters at 1 or 3 months after the trauma (table). This indicates that the groups did not differ in the mean rate of cognitive recovery from MHI.
There was no significant difference between the t w o groups in t h e number of asymptomatic patients at 1 month (chi-square = 0.67; NS) and 3 months (chi-square = 0.01; NS).
Discussion. The present results do not support the hypothesis that DGAVP affects the early cognitive recovery from an MHI. Recent evidence suggests that around 25% of patients with MHI may have persistent cognitive and neurobehavioral sequelae at 6 months p o s t i n j~r y .~~,~~ This and the positive findings in the Hijman et a1 studylo of patients with persistent postconcussional symptoms suggest that a possible DGAVP effect may be confined to a subgroup of trauma patients with different profiles of cognitive dysfunctions.
Future studies with DGAVP should focus on selected groups of mildly head-injured patients suffering from the persistent postconcussional syndrome to test the hypothesis from earlier research that positive findings with DGAVP are confined to this patient population.1°
